Results

1–10 of 146 results for Diabetic Macular Edema

Faricimab Response is Associated With Intraocular Pressure Lowering in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Tamara L Lenis, MD, PhD
Annual Meeting Talks
2024
A Randomized Trial Comparing Suprachoroidal Injection of Triamcinolone and Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema
Murat Oncel, MD, FASRS
Annual Meeting Talks
2024
12-Month Real-World Clinical and Anatomic Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2024
Obstructive Sleep Apnea as a Risk Factor for Diabetic Retinopathy Progression and Systemic Complications
Ehsan Rahimy, MD
Annual Meeting Talks
2024
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema
Yasha S Modi, MD
Updates from the Field
2025
Benefits and Value of Treatment for Diabetic Macular Edema
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2022
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema
Victor Hugo Gonzalez, MD
Updates from the Field
2024
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022